Company Overview
Snapshot
Founded in April 2009 by Igal Kushnir, RedDress operates with 11–50 employees. The company has raised a total of $42.5M across 4 funding rounds from 6 investors. In May 2023, RedDress secured a D Round.
Business overview
RedDress develops ActiGraft, an FDA-cleared regenerative wound care solution that leverages the body's natural healing capabilities. The company's proprietary patented technology enables healthcare providers to produce in vitro blood clots from a patient's whole blood in real-time. These blood clots act as a protective covering, biologic scaffold, and wound microenvironment to facilitate natural wound-healing processes. RedDress primarily serves the healthcare industry, focusing on medical devices and medical treatment, with a target market that includes both patients and providers in the Health Tech & Life Sciences sector.
Strategic signal
In July 2023, RedDress launched ActiGraft PRO with G-Code reimbursement status for the US wound care market, a significant development that enhances accessibility and adoption of their regenerative wound care solution. This move signals a strategic focus on market penetration and commercial growth in a key geographic region, indicating strong forward momentum for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is ActiGraft?
- ActiGraft is an FDA-cleared regenerative wound care solution developed by RedDress. It enables healthcare providers to produce in vitro blood clots from a patient's whole blood to promote natural wound-healing processes.
- When did RedDress secure its most recent funding round?
- RedDress secured a D Round in May 2023. The round included investments from Athoss and HCS Capital
- Has RedDress expanded its market reach in Europe?
- In September 2021, RedDress announced distribution agreements in 12 European countries, expanding the availability of its ActiGraft system.
- What is the significance of the Vizient Innovative Technology Contract for ActiGraft?
- In October 2022, RedDress received a Vizient Innovative Technology Contract for ActiGraft systems. This contract signifies recognition of ActiGraft's potential to improve patient outcomes and its innovative nature within the healthcare purchasing network.
- When did RedDress launch ActiGraft PRO with G-Code reimbursement status?
- RedDress launched ActiGraft PRO with G-Code reimbursement status for the US wound care market in July 2023, facilitating broader access and adoption of the product.